Tag Archives: ACR

October, 2018

17 October
Bristol-Myers Squibb to Showcase Immunoscience Research and Biomarker-Guided Treatment Approaches at ACR/ARHP Annual Meeting

PRINCETON, N.J–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) today announced that 28 abstracts related to ORENCIA® (abatacept) and the Company’s immunoscience pipeline will be presented at the 2018 American College of Rheumatology and Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting, October 19-24, 2018, in Chicago. The abstracts accepted for presentation include clinical and …
Share

14 November
Celltrion Presents New Data Supporting Efficacy and Safety of its Biosimilars

WASHINGTON–(BUSINESS WIRE)–New data presented today at the 2016 American College of Rheumatology (ACR) Annual Meeting demonstrate that the efficacy and safety profile of CT-P10 (biosimilar rituximab) in rheumatoid arthritis (RA) patients is comparable to patients treated with originator rituximab over 24 weeks.1,2 A total of 372 RA patients (161 patients …
Share

1 July
Rheumatology Providers, FDA Leaders Discuss Biosimilar Policy Challenges & Opportunities at National Policy Briefing

WASHINGTON, DC – Experts from the American College of Rheumatology (ACR), Food and Drug Administration (FDA), and other leading national healthcare groups spoke about the emerging biosimilars market, including key policy and regulatory questions for patients, providers and the healthcare system, during a national policy briefing held today by the …
Share

31 March
Lilly Announces Positive Results from its Late-Stage Trial of its Rheumatoid Arthritis Drug

INDIANAPOLIS, March 31, 2016 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced that detailed results of RA-BEACON — a pivotal phase 3 global study of baricitinib, a once-daily oral treatment currently under regulatory review for the treatment of moderate-to-severe rheumatoid arthritis (RA) — were …
Share

11 January
Baxalta and Coherus’ Enbrel Biosimilar Meets Primary Endpoint in Late-Stage Study

REDWOOD CITY, Calif., and BANNOCKBURN, Ill., Jan. 11, 2016 (GLOBE NEWSWIRE) — Coherus BioSciences, Inc. (NASDAQ:CHRS) and Baxalta Incorporated (NYSE:BXLT) today announced that CHS-0214, a proposed biosimilar of Enbrel® (etanercept), met its primary endpoint in a confirmatory, double-blind, randomized, controlled, two-part clinical study. This ongoing study is evaluating the efficacy and safety of CHS-0214 compared to Enbrel in patients …
Share

21 April
Federal Panel Drafts Controversial Recommendations on Breast Cancer Screening

Debate surrounding the recommended age for women to initiate breast cancer screening has caused a stir between experts, and a draft proposal from the US Preventive Services Task Force (USPSTF) could potentially cause insurers to stop covering mammograms in younger individuals. On Monday, the USPSTF issued a draft proposal saying …
Share